Agilent Technologies, Inc. $A Shares Bought by Amundi

Amundi boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 1.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,110,095 shares of the medical research company’s stock after buying an additional 13,101 shares during the quarter. Amundi’s holdings in Agilent Technologies were worth $133,944,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its stake in Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 270 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Agilent Technologies by 0.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,708,940 shares of the medical research company’s stock valued at $199,912,000 after purchasing an additional 8,151 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new position in Agilent Technologies during the first quarter valued at approximately $210,000. Citigroup Inc. boosted its position in Agilent Technologies by 40.9% during the 1st quarter. Citigroup Inc. now owns 287,999 shares of the medical research company’s stock worth $33,690,000 after purchasing an additional 83,609 shares during the period. Finally, National Bank of Canada FI boosted its position in shares of Agilent Technologies by 66.5% in the first quarter. National Bank of Canada FI now owns 223,973 shares of the medical research company’s stock worth $26,200,000 after buying an additional 89,428 shares during the period.

Insider Activity

In other news, VP Rodney Gonsalves sold 3,000 shares of the stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $154.99, for a total transaction of $464,970.00. Following the transaction, the vice president owned 31,846 shares of the company’s stock, valued at approximately $4,935,811.54. This represents a 8.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Padraig Mcdonnell sold 12,490 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the completion of the transaction, the chief executive officer directly owned 33,448 shares in the company, valued at $5,017,200. The trade was a 27.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 16,401 shares of company stock worth $2,468,962.

Agilent Technologies Trading Down 1.9%

Shares of NYSE A opened at $145.45 on Monday. The business has a 50 day simple moving average of $144.84 and a 200 day simple moving average of $128.15. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $160.27. The stock has a market cap of $41.24 billion, a price-to-earnings ratio of 31.83, a PEG ratio of 4.22 and a beta of 1.27. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96.

Agilent Technologies (NYSE:A) last posted its earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.01. The firm had revenue of $1.86 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.46 earnings per share. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 6th will be given a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, January 6th. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.25. This represents a $1.02 annualized dividend and a yield of 0.7%. Agilent Technologies’s dividend payout ratio (DPR) is currently 21.66%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on A. Evercore ISI raised their price target on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. Citigroup boosted their price objective on shares of Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Wells Fargo & Company raised their price target on shares of Agilent Technologies from $150.00 to $175.00 and gave the company an “overweight” rating in a research note on Tuesday, November 25th. Barclays boosted their target price on Agilent Technologies from $145.00 to $165.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 25th. Finally, TD Cowen increased their price objective on Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $161.08.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.